Daewon Pharmaceutical Co., Ltd. (KRX: 003220)

Daewon Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	19,581	29,982	26,970	41,697	10,439	13,004
Short-Term Investments	43,877	47.71	20,036	13,123	81.5	5,794
Cash & Short-Term Investments	63,458	30,030	47,006	54,820	10,521	18,798
Cash Growth	37.63%	-36.11%	-14.26%	421.08%	-44.03%	20.67%
Accounts Receivable	65,606	70,602	62,533	52,102	37,214	40,767
Other Receivables	5,379	2,580	3,906	2,363	4,473	7,334
Receivables	70,992	73,382	66,840	54,584	42,302	48,553
Inventory	118,340	105,078	91,847	69,690	63,798	52,159
Prepaid Expenses	781.86	488.39	426.61	353.29	182.28	193.01
Other Current Assets	1,851	314.56	1,165	929.46	474.22	1,846
Total Current Assets	255,423	209,293	207,284	180,377	117,276	121,548
Property, Plant & Equipment	200,705	160,092	158,912	166,674	157,252	157,636
Long-Term Investments	47,947	84,647	36,443	28,081	25,233	14,520
Goodwill	-	7,254	11,328	11,549	245.57	245.57
Other Intangible Assets	46,898	16,121	13,603	13,916	11,617	11,177
Long-Term Accounts Receivable	-0	-	-	-	-	-
Long-Term Deferred Tax Assets	7,225	7,985	6,694	9,616	7,296	8,331
Long-Term Deferred Charges	-	18,096	15,142	14,977	11,809	9,046
Other Long-Term Assets	24,642	4,510	4,144	4,390	4,477	4,811
Total Assets	582,840	507,998	453,550	429,580	335,214	327,532
Accounts Payable	20,350	20,910	19,583	17,222	10,687	8,936
Accrued Expenses	5,316	4,885	4,352	3,741	3,220	3,043
Short-Term Debt	88,534	69,651	52,768	42,543	20,000	20,000
Current Portion of Long-Term Debt	41,969	39,803	9,284	8,822	1,500	-
Current Portion of Leases	1,433	1,123	1,344	362.95	948.28	848.93
Current Income Taxes Payable	4,262	2,485	4,913	4,367	1,244	5,459
Other Current Liabilities	52,326	43,833	35,903	25,019	18,417	23,455
Total Current Liabilities	214,190	182,690	128,146	102,076	56,017	61,740
Long-Term Debt	57,832	34,575	52,119	69,625	28,500	30,000
Long-Term Leases	1,539	897.72	961.42	2,616	1,530	316.12
Other Long-Term Liabilities	76.12	73.5	80	80	932.18	799.49
Total Liabilities	302,861	243,734	204,785	211,176	122,442	123,316
Common Stock	11,095	11,095	10,982	10,612	10,122	9,831
Additional Paid-In Capital	13,483	13,483	11,789	9,530	9,283	9,578
Retained Earnings	257,694	255,790	241,595	204,827	200,464	188,265
Treasury Stock	-15,063	-15,063	-15,063	-8,891	-8,806	-3,743
Comprehensive Income & Other	660.08	892.92	1,643	3,221	2,875	1,009
Total Common Equity	267,870	266,199	250,947	219,299	213,938	204,941
Minority Interest	12,109	-1,934	-2,182	-894.85	-1,166	-724.42
Shareholders' Equity	279,979	264,264	248,765	218,404	212,772	204,216
Total Liabilities & Equity	582,840	507,998	453,550	429,580	335,214	327,532
Total Debt	191,307	146,050	116,476	123,968	52,478	51,165
Net Cash (Debt)	-127,849	-116,020	-69,471	-69,148	-41,957	-32,367
Net Cash Per Share	-5896.70	-5356.37	-3175.72	-3258.76	-1965.93	-1500.51
Filing Date Shares Outstanding	21.2	21.2	20.97	20.6	20.21	20.94
Total Common Shares Outstanding	21.2	21.2	20.97	21.22	21.22	21.57
Working Capital	41,233	26,603	79,137	78,301	61,259	59,808
Book Value Per Share	12637.73	12558.89	11966.66	10335.27	10080.10	9500.90
Tangible Book Value	220,972	242,823	226,017	193,833	202,075	193,518
Tangible Book Value Per Share	10425.17	11456.07	10777.82	9135.12	9521.15	8971.34
Land	-	36,957	36,957	37,055	33,951	33,972
Buildings	-	107,803	107,710	79,558	89,713	53,769
Machinery	-	101,791	100,149	41,553	86,513	62,706
Construction In Progress	-	10,692	778.36	1,585	1,051	53,947

Source: S&P Capital IQ. Standard template. Financial Sources.